With seven or eight states now imposing different transparency requirements on drug companies, harmonizing those requirements under federal law is a high priority for the pharmaceutical industry, Lisa Joldersma, senior vice president for insurance and state issues at Pharmaceutical Research and Manufacturers of America, told a U.S. House subcommittee Tuesday.